Kenya Gets 21,000 Doses of Twice-Yearly HIV Prevention Drug

Kenya just became one of the first countries to receive Lenacapavir, a revolutionary HIV prevention drug that requires just two shots per year instead of daily pills.

The Ministry of Health announced the arrival of 21,000 starter doses in partnership with the Global Fund, marking a major step forward in the country's fight against HIV. Another 12,000 continuation doses will arrive in April, with 25,000 additional doses coming from the U.S. Government to support the initial rollout.

Starting in March 2026, the twice-yearly injectable will be available in 15 counties with the highest HIV rates. The phased approach ensures healthcare facilities are ready and supplies remain steady as the program expands nationwide.

The drug represents a massive improvement over current prevention methods. Daily oral medications require strict adherence that many people struggle to maintain. Lenacapavir's twice-yearly schedule removes that daily burden entirely, making consistent HIV prevention achievable for thousands more Kenyans.

Director-General for Health Dr. Patrick Amoth emphasized the drug's proven safety record. The U.S. Food and Drug Administration approved it in June 2025, followed by World Health Organization endorsement in July. Kenya's own Pharmacy and Poisons Board completed its review and registered the drug in January 2026.

The cost breakthrough makes this rollout even more remarkable. Patients will receive the treatment for about 7,800 Kenyan shillings per year (roughly $60). That's a dramatic drop from its previous price tag of $42,000 annually.

The Ripple Effect

This advancement strengthens Kenya's entire HIV prevention ecosystem. The drug supports efforts to prevent mother-to-child transmission, working toward the national goal of ensuring every child is born HIV-free and stays that way.

The initiative aligns with Kenya's Universal Health Coverage agenda, making cutting-edge prevention accessible rather than available only to those who can afford premium healthcare. Communities that have borne the heaviest burden of HIV will be first in line for this protection.

Healthcare workers will have a powerful new tool to offer people at high risk, especially those who found daily medication schedules impossible to maintain. The long-acting formula means fewer missed doses and better protection for vulnerable populations.

Kenya's leadership in bringing this innovation to its people showcases what's possible when global partnerships, scientific advancement, and public health commitment come together with urgency and purpose.